CSL Behring is is a biopharmaceutical company committed to improving the quality of life for people with rare and serious diseases worldwide, manufacturing plasma-derived and recombinant therapeutic products and providing them to people in more than 100 countries. This commitment is reflected in their support of programs and activities for patients with rare plasma-protein related diseases, including bleeding disorders and primary immune deficiencies.
Von Willebrand disease (VWD) is the most common hereditary blood-clotting disorder in humans. Patients suffering from VWD have too little coagulation protein in their body. This deficiency makes it harder for the blood to clot when bleeding occurs. Although most patients experience little trouble with their disease, they must be careful with serious injuries or operations.
Haemate® P is used for the prevention and treatment of bleedings or surgical bleeding caused by the lack of von Willebrand factor.
A website was created to inform physicians at Erasmus MC about Haemate® P and how it works. Through its clear and distinctive style, the website for Haemate® P is recognizable for every physician. The website shows the characteristics of the drug in a clear brief overview, which allows the user to learn about all its features in just one glance.
The purpose of the design is that physicians can learn more about Haemate® P. Additionally, that they can use a calculator on the website to discover the differences and similarities between Haemate® P and other drugs against VWD, such as Wilate.
The strong characteristics of Haemate® P are visualized in 3 core illustrations. The rest of the website exudes a clear and purposeful style, which is inspired by election campaigns.
In addition to the desktop version, I also designed a mobile version.
"Can I have the URL of this prototype, please?" — User tester